Nowadays, the PD-1/PD-L1 and CTLA-4/CD28 pathways have been extensively studied, and multiple ICIs targeting these pathways have been approved for systemic therapy of advanced ccRCC. The gene discussed is CD274; the disease is nonpapillary renal cell carcinoma.